[go: up one dir, main page]

WO2003099215A3 - Antisense modulation of glucocorticoid receptor expression - Google Patents

Antisense modulation of glucocorticoid receptor expression Download PDF

Info

Publication number
WO2003099215A3
WO2003099215A3 PCT/US2003/016084 US0316084W WO03099215A3 WO 2003099215 A3 WO2003099215 A3 WO 2003099215A3 US 0316084 W US0316084 W US 0316084W WO 03099215 A3 WO03099215 A3 WO 03099215A3
Authority
WO
WIPO (PCT)
Prior art keywords
glucocorticoid receptor
receptor expression
antisense modulation
expression
antisense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/016084
Other languages
French (fr)
Other versions
WO2003099215A2 (en
Inventor
Seth D Crosby
Amy E Nalseth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Priority to JP2004506742A priority Critical patent/JP2005525829A/en
Priority to AU2003233634A priority patent/AU2003233634A1/en
Priority to EP03729073A priority patent/EP1534728A4/en
Publication of WO2003099215A2 publication Critical patent/WO2003099215A2/en
Anticipated expiration legal-status Critical
Publication of WO2003099215A3 publication Critical patent/WO2003099215A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides compositions and methods for modulating the expression of mammalian glucocorticoid receptor. In particular, this invention relates to antisense compounds, particularly oligonucleotides, specifically hybridizable with nucleic acids encoding human glucocorticoid receptor.
PCT/US2003/016084 2002-05-20 2003-05-20 Antisense modulation of glucocorticoid receptor expression Ceased WO2003099215A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2004506742A JP2005525829A (en) 2002-05-20 2003-05-20 Antisense regulation of glucocorticoid receptor expression
AU2003233634A AU2003233634A1 (en) 2002-05-20 2003-05-20 Antisense modulation of glucocorticoid receptor expression
EP03729073A EP1534728A4 (en) 2002-05-20 2003-05-20 Antisense modulation of glucocorticoid receptor expression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38185702P 2002-05-20 2002-05-20
US60/381,857 2002-05-20

Publications (2)

Publication Number Publication Date
WO2003099215A2 WO2003099215A2 (en) 2003-12-04
WO2003099215A3 true WO2003099215A3 (en) 2005-03-31

Family

ID=29584332

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/016084 Ceased WO2003099215A2 (en) 2002-05-20 2003-05-20 Antisense modulation of glucocorticoid receptor expression

Country Status (4)

Country Link
EP (1) EP1534728A4 (en)
JP (1) JP2005525829A (en)
AU (1) AU2003233634A1 (en)
WO (1) WO2003099215A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969316B2 (en) 2006-05-05 2015-03-03 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of DGAT2

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005071080A2 (en) * 2004-01-20 2005-08-04 Isis Pharmaceuticals, Inc. Modulation of glucocorticoid receptor expression
EP1799859B1 (en) * 2004-09-17 2014-07-02 Isis Pharmaceuticals, Inc. Enhanced antisense oligonucleotides
AU2006292293B2 (en) 2005-09-19 2012-09-13 Isis Pharmaceuticals, Inc. Modulation of glucocorticoid receptor expression
JP2009171895A (en) * 2008-01-24 2009-08-06 Hitachi Software Eng Co Ltd Functional analysis method of nuclear noncoding RNA
JP2012526533A (en) * 2009-05-15 2012-11-01 エフ．ホフマン−ラ ロシュ アーゲー Compositions and methods for inhibiting the expression of glucocorticoid receptor (GCR) gene
EP2545173A2 (en) 2010-03-12 2013-01-16 Sarepta Therapeutics, Inc. Antisense modulation of nuclear hormone receptors
HK1201555A1 (en) 2011-10-25 2015-09-04 Isis Pharmaceuticals, Inc. Antisense modulation of gccr expression
US9234200B2 (en) * 2011-12-15 2016-01-12 National University Of Corporation Tokyo University Of Agriculture And Technology Oligonucleotide, glucocorticoid sensitivity enhancer, pharmaceutical composition, and expression vector
WO2016077704A1 (en) * 2014-11-14 2016-05-19 The Regents Of The University Of California Modulation of agpat5 expression
WO2019222513A1 (en) * 2018-05-17 2019-11-21 Regents Of The University Of Minnesota Drug-resistant immune cells and methods of use thereof
WO2024245930A2 (en) * 2023-05-26 2024-12-05 E-Therapeutics Plc Inhibitors of expression and/or function

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5929058A (en) * 1996-12-24 1999-07-27 Zymogenetics, Inc. Treatment agents and methods for treating type II diabetes and symptoms of type II diabetes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ENGELMANN, M. ET AL.: "Downregulation of Brain Mineralocorticoid and Glucocorticoid Receptor by Antisense Oligonucleotide Treatment Fails to Alter Spatial Navigation by Rats", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 361, 1998, pages 17 - 26, XP002984841 *
KORTE, S.M. ET AL.: "Antisense to the Glucocorticoid Receptor in Hippocampal Dentate Gyrus Reduces Immobility in forced Swim Test", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 301, 1996, pages 19 - 25, XP002984840 *
PEPIN, M.C. ET AL.: "Impaired Type II Glucocorticoid-Receptor Function in Mice Bearing Antisense RNA Transgene", NATURE, vol. 335, 20 February 1992 (1992-02-20), pages 725 - 728, XP001088468 *
See also references of EP1534728A4 *
STECKLER, T. ET AL.: "Glucocorticoid Receptor Impairment Enhances Impulsive Responding in Transgenic Mice Performing on a Simultaneous Visual Discrimination Task", EUROPEAN JOURNAL OF NEUROSCIENCE, vol. 12, 2000, pages 2559 - 2569, XP002984842 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969316B2 (en) 2006-05-05 2015-03-03 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of DGAT2

Also Published As

Publication number Publication date
EP1534728A2 (en) 2005-06-01
EP1534728A4 (en) 2005-10-26
AU2003233634A8 (en) 2003-12-12
AU2003233634A1 (en) 2003-12-12
JP2005525829A (en) 2005-09-02
WO2003099215A2 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
WO2002036743A3 (en) Antisense modulation of calreticulin expression
WO2004005460A3 (en) Antisense modulation of hmg-coa reductase expression
WO2004030750A8 (en) Antisense modulation of farnesoid x receptor expression
WO2003012057A3 (en) Antisense modulation of serum amyloid a4 expression
AU2001290706A1 (en) Antisense modulation of clusterin expression
WO2004044181A3 (en) Antisense modulation of apolipoprotein b expression
WO2002092772A3 (en) Antisense modulation of ptp1b expression
WO2004011610A3 (en) Antisense modulation of polo-like kinase expression
WO2004071407A3 (en) Antisense modulation of ptp1b expression
WO2003097662A8 (en) Antisense modulation of apolipoprotein b expression
WO2003052072A3 (en) Antisense modulation of estrogen receptor alpha expression
WO2003010284A3 (en) Antisense modulation of c-reactive protein expression
WO2003099215A3 (en) Antisense modulation of glucocorticoid receptor expression
WO2003000656A3 (en) Antisense modulation of transforming growth factor beta receptor ii expression
WO2003053341A3 (en) Antisense modulation of ship-1 expression
WO2003057843A8 (en) Methods and materials for modulating trpc4
WO2003104397A3 (en) Antisense modulation of g protein-coupled receptor kinase 6 expression
WO2002095053A3 (en) Antisense modulation of src-c expression
WO2003088921A3 (en) Antisense modulation of hydroxysteroid 11-beta dehydrogenase 1 expression
WO2003050244A3 (en) Antisense modulation of g protein-coupled receptor etbr-lp-2 expression
WO2003052062A3 (en) Antisense modulation of cd36l1 expression
WO2003057847A3 (en) METHODS AND MATERIALS FOR MODULATING ENaC-BETA
WO2003099224A3 (en) Antisense moodulation of kinesin-like 1 expression
WO2003070878A3 (en) Antisense modulation of hematopoietic cell protein tyrosine kinase expression
WO2004003201A3 (en) Antisense modulation of lrh1 expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004506742

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003729073

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003729073

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWW Wipo information: withdrawn in national office

Ref document number: 2003729073

Country of ref document: EP